<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101264860</journal-id><journal-id journal-id-type="pubmed-jr-id">32902</journal-id><journal-id journal-id-type="nlm-ta">Obesity (Silver Spring)</journal-id><journal-id journal-id-type="iso-abbrev">Obesity (Silver Spring)</journal-id><journal-title-group><journal-title>Obesity (Silver Spring, Md.)</journal-title></journal-title-group><issn pub-type="ppub">1930-7381</issn><issn pub-type="epub">1930-739X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">25865294</article-id><article-id pub-id-type="pmc">4414748</article-id><article-id pub-id-type="doi">10.1002/oby.21069</article-id><article-id pub-id-type="manuscript">NIHMS662890</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Oxytocin reduces caloric intake in men</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lawson</surname><given-names>Elizabeth A.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marengi</surname><given-names>Dean A.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>DeSanti</surname><given-names>Rebecca L.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Holmes</surname><given-names>Tara M.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schoenfeld</surname><given-names>David A.</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Tolley</surname><given-names>Christiane J.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
</aff><aff id="A2"><label>2</label>Harvard Catalyst Clinical Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
</aff><aff id="A3"><label>3</label>Department of Biostatistics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
</aff><author-notes><corresp id="CR1">Correspondence: Elizabeth A. Lawson, M.D., M.M.Sc., Neuroendocrine Unit, Massachusetts General Hospital, 55 Fruit St. Boston, MA 02114; ph: 617-726-3870; fax: 617-726-5072; <email>ealawson@partners.org</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>11</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>10</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>5</month><year>2016</year></pub-date><volume>23</volume><issue>5</issue><fpage>950</fpage><lpage>956</lpage><!--elocation-id from pubmed: 10.1002/oby.21069--><permissions><license xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms"><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:<ext-link ext-link-type="uri" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</ext-link></license-p></license></permissions><abstract><sec id="S1"><title>Objective</title><p id="P1">Preclinical studies indicate that oxytocin is anorexigenic and has beneficial metabolic effects. Oxytocin effects on nutrition and metabolism in humans are not well defined. We hypothesized that oxytocin would reduce caloric intake and appetite, and alter levels of appetite-regulating hormones. We also explored metabolic effects of oxytocin.</p></sec><sec id="S2"><title>Methods</title><p id="P2">We performed a randomized, placebo-controlled crossover study of single-dose intranasal oxytocin (24 IU) in 25 fasting healthy men. After oxytocin/placebo, subjects selected breakfast from a menu, and were given double portions. Caloric content of food consumed was measured. Visual analogue scales were used to assess appetite and blood was drawn for appetite-regulating hormones, insulin, and glucose before and after oxytocin/placebo. Indirect calorimetry assessed resting energy expenditure (REE) and substrate utilization.</p></sec><sec id="S3"><title>Results</title><p id="P3">Oxytocin reduced caloric intake with a preferential effect on fat intake and increased levels of the anorexigenic hormone cholecystokinin without affecting appetite or other appetite-regulating hormones. There was no effect of oxytocin on REE. Oxytocin resulted in a shift from carbohydrate to fat utilization and improved insulin sensitivity.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">Intranasal oxytocin reduces caloric intake and has beneficial metabolic effects in men without concerning side effects. The efficacy and safety of sustained oxytocin administration in the treatment of obesity warrants investigation.</p></sec></abstract><kwd-group><kwd>Oxytocin</kwd><kwd>obesity</kwd><kwd>nutrition</kwd><kwd>glucose homeostasis</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="S5"><title>Introduction</title><p id="P5">Obesity is a major public health concern, affecting more than one-third of the U.S. adult population and associated with significant morbidity, including higher rates of diabetes and increased mortality(<xref rid="R1" ref-type="bibr">1</xref>). Although complications from obesity may be reversible with weight loss, meaningful weight reduction is difficult to achieve. There are few treatment options available to supplement lifestyle modifications. Bariatric surgery is effective, but invasive and associated with complications(<xref rid="R2" ref-type="bibr">2</xref>). FDA-approved medications result in modest weight loss, but this effect is not sustained, and the drugs are associated with significant side effects(<xref rid="R3" ref-type="bibr">3</xref>). There is a need for effective, tolerable therapies for obesity.</p><p id="P6">In animal models, oxytocin, a peptide hormone primarily produced in the supraoptic (SON) and paraventricular (PVN) hypothalamic nuclei, is anorexigenic(<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>). Administration of oxytocin to rats reduces caloric intake, and this effect is reversed by first giving an oxytocin antagonist(<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>). Oxytocin induces weight loss in rodents, and this effect may be related to increased energy expenditure and lipolyis in addition to appetite suppression(<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>). Preclinical studies indicate that oxytocin has positive metabolic effects(<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>). The role of oxytocin in regulating nutrition and metabolism in humans is only beginning to be understood (<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>).</p><p id="P7">Oxytocin administered intranasally has central actions with minimal side effects, and is appealing as a potential targeted therapy for obesity(<xref rid="R15" ref-type="bibr">15</xref>). We performed a randomized, double-blind, placebo-controlled crossover study investigating oxytocin effects on caloric intake. We hypothesized that a single dose of intranasal oxytocin would decrease food intake at a subsequent meal. We also predicted that oxytocin would reduce appetite and modulate appetite-regulating hormone levels. Finally, we explored metabolic effects of oxytocin, hypothesizing that oxytocin would result in an increase in resting energy expenditure (REE), fat utilization and insulin sensitivity.</p></sec><sec sec-type="methods" id="S6"><title>Methods and Procedures</title><sec sec-type="subjects" id="S7"><title>Subjects</title><p id="P8">We studied 25 healthy men, 18-45 years old: 13 normal-weight (NW) and 12 overweight/obese men (OB) recruited from the community. Body mass index (BMI) was 18.5-24.9 for NW and 25-40 for OB. Subjects were required to have had a stable weight for three months and to eat breakfast &#x02265;4 times/week.</p><p id="P9">Subjects were excluded for psychiatric disease, psychotropic medications, eating disorder history by structured clinical interview for DSM disorders-IV (SCID), excessive exercise within three months (running&#x0003e;25 miles or exercising &#x0003e;10 hours in any one week), diabetes, substance abuse, anemia, gastrointestinal surgery, cardiovascular disease, untreated thyroid disease, and smoking.</p></sec><sec id="S8"><title>Protocol</title><p id="P10">This study was approved by Partners Human Research Committee. Written informed consent was obtained. Subjects were admitted to the Massachusetts General Hospital (MGH) Clinical Research Center (CRC) for outpatient screening and two main study visits. The first and second main study visits took place one to eight weeks apart.</p><p id="P11">At the screen, height and weight were measured, blood was drawn, and a history and physical exam were performed. BMI was obtained [weight (kg)/height (m<sup>2</sup>). Exercise patterns were assessed by history and the Paffenbarger activity assessment. A food diary was provided to subjects to track food intake during the 72 hours before the first main study visit. The disordered eating modules of the SCID were administered by trained study personnel. Subjects were advised to avoid alcohol and strenuous exercise for 24 hours and to fast for 12 hours before main visits.</p><p id="P12"><xref ref-type="fig" rid="F1">Figure 1</xref> shows the study schema. At main study visits, weight and BMI were assessed. The food diary from the first visit was collected and reviewed with the subject, and a second diary was provided for documentation of food intake in the 72 hours prior to the second visit. A copy of the food diary collected at the first visit was returned to the subject, who was asked to replicate food intake from the 72 hours prior to the first visit in the 72 hours prior to the second visit. Food records were reviewed by a dietician. Medical history was updated. Intranasal oxytocin (Syntocinon, Novartis) (24 IU) or placebo (same inactive ingredients and packaging) was self-administered (3 sprays per nostril) under the supervision of a nurse practitioner at approximately 07:30am. The research pharmacy randomized the visit order in which subjects received drug or placebo. Subjects and study personnel were blinded to the randomization. An intravenous catheter was placed and blood was drawn immediately prior and 15, 30, and 55 minutes after oxytocin/placebo. Vital signs were obtained immediately prior and 15 minutes after oxytocin/placebo. Heart rate and blood pressure were repeated at 55 and 120 minutes post-oxytocin/placebo. Appetite was assessed using visual analogue scales (VAS) before and 55 minutes after oxytocin/placebo. Subjects were offered a menu (<xref ref-type="supplementary-material" rid="SD1">Supplemental Figure 1</xref>) 15 minutes after oxytocin/placebo and told to order whatever amount of food they thought they could eat. Indirect calorimetry was performed (VMAX Encore 29 metabolic cart, Viasys Healthcare, Carefusion; San Diego, CA) to assess fasting REE and respiratory quotient (RQ) 30 minutes post-oxytocin/placebo. Substrate utilization was calculated: carbohydrate oxidation (g/min) = 4.21*VCO<sub>2</sub>-2.962*VO<sub>2</sub>-0.4*n; fat oxidation (g/min) = 1.695*VO<sub>2</sub>- 1.701*VCO<sub>2</sub>-1.77*n, where n represents nitrogen excretion from protein oxidation (estimated at 135 mg*kg*min<sup>&#x02212;1</sup>)(<xref rid="R16" ref-type="bibr">16</xref>). Sixty minutes after oxytocin/placebo, subjects were offered two of every food item ordered and given 30 minutes to eat, followed by quantification of nutrient intake. Subjects ate the meal in a private room without disruption. Side effects were systematically assessed at the end of each visit.</p></sec><sec id="S9"><title>Bionutrition measures</title><p id="P13">The menu was created using ProNutra (Viocare; Princeton, NJ) and managed as an individualized weighed diet. Each item had a known weight and remaining food was weighed back. Nutrient analysis investigated the difference between prepared and consumed total calories and fat, carbohydrate, and protein content. VAS, a reliable method to assess appetite(<xref rid="R17" ref-type="bibr">17</xref>), were administered fasting before and after oxytocin/placebo. Subjects were asked to make a mark on a 100 mm line with extremes on either end indicating how they felt at that moment. Scores were calculated by measuring the distance from the left side of the line. The following were assessed: hunger, desire to eat preferred foods, satisfaction, fullness, quantity one could eat, desire for specific types of foods (sweet, salty, savory, and fatty), and nausea.</p></sec><sec id="S10"><title>Biochemical analysis</title><p id="P14">Plasma glucose was measured by LabCorp. Serum and plasma samples were stored at &#x02212;80&#x000b0; C. Triglycerides were measured on the ARCHITECT c System&#x02122; [ci8200, Abbott Diagnostics Division, Abbott Park IL] by the glycerol phosphate oxidase assay using ACS grade glycerol calibrators traceable to gravimeteric reference methods [inter-assay coefficients of variation (CV) for controls 1.5-2.5%]. Oxytocin was measured in unextracted serum by ELISA (Assay Designs, Inc., Ann Arbor, MI). A new (2013) polyclonal rabbit antibody has increased specificity to non-human mesotocin and Arg8-vasotocin, but otherwise showed no specificity differences. Calibration curve statistics and in-house quality controls (QC) were monitored. The detection limit was 12.5 pg/mL. In house QCs had a mean of 152 and 338 pg/mL, respectively and inter-assay CV of 15 and 18%, respectively. Active serum cholecystokinin (CCK) peptide levels were measured at baseline and 30 and 55 min after oxytocin/placebo using an ELISA (Abnova, Walnut, CA; intra-assay and inter-assay CVs &#x0003c;10% and &#x0003c;15%, respectively; detection limit 12.5 pg/mL). Plasma for ghrelin was collected in tubes containing 10mg/mL PMSF and 1N HCL. Active ghrelin was measured using an ELISA (EMD Millipore, Billerica, MA; inter-assay CV&#x0003c;12%, detection limit 10 pg/mL). Serum insulin was measured using a chemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN; inter-assay CV &#x0003c;3%, detection limit 0.2 uU/mL). HOMA-IR was calculated: Insulin (uU/mL) &#x000d7; Glucose (mmol/L)/22.5. Serum leptin was measured using an ELISA (EMD Millipore; inter-assay CV&#x0003c;9%, detection limit 0.25 ng/mL). Serum PYY was measured using an electrochemiluminescent assay (Meso Scale Discovery, Gaithersburg, MD; inter-assay CV &#x0003c;12%, detection limit 70 pg/mL).</p></sec><sec id="S11"><title>Data analysis</title><p id="P15">The crossover study was analyzed using an analysis of variance with a period, treatment and patient effect and a baseline value as covariate when available. We used the same model to test for a group (NW, OB)-treatment interaction to determine whether the treatment effect was different in NW vs. OB. We used a repeated measures analysis of variance with the terms above, and time, for analyzing those measures which were measured repeatedly during each visit. The treatment effect that is calculated by this model is essentially the mean difference between outcomes for each treatment averaged over the time points corrected for possible covariate, period, subject, and missing value effects.</p></sec></sec><sec sec-type="results" id="S12"><title>Results</title><sec sec-type="subjects" id="S13"><title>Subjects</title><p id="P16">Mean age was 27.1&#x000b1;1.5 (mean&#x000b1;SEM) years old. NW were younger than OB (23.9&#x000b1;1.9 vs. 30.6&#x000b1;2.0 yrs, p=0.02). Mean weight and BMI were 80.7&#x000b1;17.8 kg and 26.1&#x000b1;1.2 kg/m<sup>2</sup>, and were lower in NW than OB (weight: 67.4&#x000b1;2.2 vs. 95.2&#x000b1;3.9 kg, p&#x0003c;0.0001; BMI: 21.2&#x000b1;0.3 vs. 31.5&#x000b1;1.2 kg/m<sup>2</sup>, p&#x0003c;0.0001). Subjects ate breakfast 5.6&#x000b1;0.2 days/week on average, and this did not differ by group [5.8&#x000b1;0.3 (NW) vs. 5.3&#x000b1;0.4 (OB) days, p=0.3]. Across groups, mean exercise assessed by history was 3.4&#x000b1;0.6 hours per week, and vigorous activity assessed by Paffenbarger was 5.2&#x000b1;0.9 hours per week. Reported activity levels did not differ by group [exercise/week: 5.8&#x000b1;0.3 (NW) vs. 5.3&#x000b1;0.4 (OB) hours, p=0.9; vigorous activity/week: 5.2&#x000b1;0.9 (NW) vs. 5.3&#x000b1;1.0 (OB) hours, p=1.0]. Recorded food intake in the 72 hours leading up to oxytocin and placebo visits did not differ within subjects (<xref ref-type="table" rid="T1">Table 1</xref>).</p></sec><sec id="S14"><title>Caloric intake and appetite</title><p id="P17"><xref ref-type="table" rid="T1">Table 1</xref> shows oxytocin effects on energy intake. Oxytocin did not impact caloric content of food ordered from the menu. Oxytocin reduced the total caloric intake by 122&#x000b1;51 kcal (p=0.03) (<xref ref-type="fig" rid="F2">Figure 2</xref>). Group (NW vs. OB) did not affect results. Oxytocin reduced fat intake by 8.7&#x000b1;3.8 g (p=0.03; NS after controlling for multiple comparisons). Protein (&#x02212;3.9&#x000b1;2.2 g) and carbohydrate (&#x02212;7.2&#x000b1;9.4 g) intake were reduced, but this was not statistically significant. Oxytocin did not significantly impact subjective appetite measures.</p></sec><sec id="S15"><title>Indirect calorimetry and triglyceride levels</title><p id="P18"><xref ref-type="table" rid="T1">Table 1</xref> shows indirect calorimetry results. While REE was not changed by oxytocin administration, RQ was reduced (&#x02212;0.03&#x000b1;0.01, p=0.02). Oxytocin reduced carbohydrate utilization (&#x02212;0.02&#x000b1;0.01, p=0.03) and increased fat utilization (0.01&#x000b1;0.00, p=0.04). There was a trend toward reduction of triglyceride levels following oxytocin (&#x02212;1.8 mg/dL, p=0.07) (<xref ref-type="table" rid="T2">Table 2</xref>).</p></sec><sec id="S16"><title>Fasting appetite hormones</title><p id="P19"><xref ref-type="table" rid="T2">Table 2</xref> presents appetite regulating hormones. Oxytocin resulted in increased levels of CCK (10.9&#x000b1;3.1 pg/mL, p=0.002). However, the increase in CCK levels were not related to caloric intake. There was no treatment effect on oxytocin (p=0.1), leptin (p=0.5), ghrelin (p=0.2) or PYY (p=0.8) levels.</p></sec><sec id="S17"><title>Glucose homeostasis</title><p id="P20"><xref ref-type="table" rid="T2">Table 2</xref> shows fasting insulin and glucose levels and HOMA-IR. Oxytocin reduced average insulin levels (&#x02212;1.7&#x000b1;0.8 uU/mL, p=0.04) and HOMA-IR (&#x02212;0.4, p=0.04) over the time points but had no effect on glucose levels. At baseline, HOMA-IR was higher in OB than NW (2.1&#x000b1;0.4 vs. 0.9&#x000b1;0.1, p=0.04). There was no significant difference in treatment effect on OB vs. NW.</p></sec><sec id="S18"><title>Safety and tolerability</title><p id="P21">Oxytocin did not affect blood pressure or heart rate. There was a slight decrease in temperature 15 minutes after administration (&#x02212;0.3 &#x000b0;F, p=0.006). There were few adverse events in the study, none of which was severe (<xref ref-type="table" rid="T3">Table 3</xref>), with no difference between oxytocin and placebo conditions.</p></sec></sec><sec sec-type="discussion" id="S19"><title>Discussion</title><p id="P22">In a study of men across a spectrum of weights, we report that a single dose of intranasal oxytocin reduces total caloric intake at a subsequent meal. The effect size of 122 kcal may be clinically relevant, as this would amount to 366 kcal/day or about 4 kg over twelve weeks and more than 17 kg over a year if the effect of oxytocin is equivalent over three meals per day and sustained over time. To put this into context, currently FDA-approved medications for obesity lead to 3.2-8.9 kg weight loss at one year(<xref rid="R3" ref-type="bibr">3</xref>). Further research will be important to establish whether the reduction in nutritional intake continues and leads to weight loss with sustained intranasal oxytocin.</p><p id="P23">In animal models, oxytocin administration reduces food intake and an oxytocin antagonist reverses this effect(<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>). Heterozygous mice for single-minded 1, a gene responsible for hyperphagic obesity in humans, have low levels of hypothalamic oxytocin mRNA, and administration of oxytocin in these animals reverses excessive food intake and weight gain(<xref rid="R18" ref-type="bibr">18</xref>). Whether oxytocin is anorexigenic in humans has not been well established. Borg reported that in 10 healthy adults, 40 mU/min IV oxytocin, but not 20 mU/min or 80 mU/min, <italic>reduced</italic> satiety without affecting volume of intake of a liquid meal(<xref rid="R13" ref-type="bibr">13</xref>). In contrast, our study used intranasal oxytocin which may have central in addition to peripheral effects(<xref rid="R19" ref-type="bibr">19</xref>). An investigation by Ott et al. in 20 healthy men did not find an acute effect of intranasal oxytocin on caloric intake at a breakfast buffet. Possible explanations for the differences in our results include differences in food intake leading up to study visits (our subjects were asked to consume the same caloric content in the 72 hours preceding each of their two visits) or anticipatory effects (our subjects selected food from a menu prior to the meal). Although Ott&#x02019;s study did not show an effect of oxytocin on breakfast intake, it did demonstrate reduced <italic>postprandial</italic> consumption of a snack, particularly chocolate cookies, suggesting an effect on reward-driven feeding(<xref rid="R14" ref-type="bibr">14</xref>). Neither our study nor Ott&#x02019;s identified an effect of oxytocin on subjective appetite(<xref rid="R14" ref-type="bibr">14</xref>). Side effects, such as nausea, did not differ between oxytocin and placebo in our study, and therefore do not explain oxytocin&#x02019;s effect on food intake. Further studies will be important to define the mechanisms underlying oxytocin&#x02019;s reduction of caloric intake.</p><p id="P24">Several food motivation pathways, including those involving leptin, alpha-MSH and AgRP, converge on oxytocin neurons(<xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>). Parvocellular neurons of the PVN extend to the caudal brainstem, where they regulate autonomic control of feeding(<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>). Oxytocin is also released by dendrites of magnocellular neurons of the PVN and SON, and may reduce food intake in part via diffusion to the ventromedial nucleus, a satiety-regulating brain region rich in oxytocin receptors(<xref rid="R25" ref-type="bibr">25</xref>). Axonal release of oxytocin from the PVN may also have effects on hedonic food consumption via dopaminergic mesolimbic neurons in the ventral tegmental area (VTA)(<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>, <xref rid="R27" ref-type="bibr">27</xref>). In rats, acute administration of oxytocin into the VTA suppresses sucrose intake(<xref rid="R28" ref-type="bibr">28</xref>). Furthermore, Blevins et al. have demonstrated that chronic administration of oxytocin reduces consumption of fructose-sweetened beverage in obese nonhuman primates(<xref rid="R11" ref-type="bibr">11</xref>). Oxytocin may also reduce food intake by inhibiting gastric emptying. Studies in rats demonstrate that intraperitoneal oxytocin increases levels of the peripheral satiety hormone CCK and inhibits gastric emptying; these effects are blocked by administration of a CCK-1 receptor antagonist(<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>). We found that intranasal oxytocin resulted in an increase in serum CCK levels preceding suppression of food intake. However, it is not clear whether CCK is a mediator of oxytocin effects as we did not find a relationship between change in CCK levels and food consumption. Whether oxytocin has indirect effects on food intake mediated by other hormones is unknown. Although another study found that intravenous oxytocin reduced total ghrelin levels, ours did not find an effect of intranasal oxytocin on levels of acylated ghrelin, the active form of ghrelin with established orexigenic properties(<xref rid="R31" ref-type="bibr">31</xref>). The discrepancy in findings may be due to differences in oxytocin dosage or mode of administration, or the form of ghrelin measured. We found no effect of oxytocin on levels of leptin or PYY, indicating that oxytocin&#x02019;s suppression of caloric intake is not mediated by changes in these hormones.</p><p id="P25">We did not find an increase in serum oxytocin levels in the oxytocin vs. placebo condition. Given the short half life of oxytocin in blood (approximately 3-5 minutes), it is possible that we did not capture a brief increase in peripheral levels at the sampled timepoints. Alternatively, intranasal oxytocin effects may be central, and not reflected in peripheral levels. Although central oxytocin in some cases may stimulate peripheral oxytocin secretion (<xref rid="R7" ref-type="bibr">7</xref>), there is evidence that stimulation of oxytocin secretion in appetite pathways is accompanied by inhibition of peripheral secretion of oxytocin via the posterior pituitary(<xref rid="R22" ref-type="bibr">22</xref>). It is therefore possible that the nonsignificant reduction in peripheral oxytocin levels we found in response to intranasal oxytocin in the context of food anticipation was due to oxytocinergic activity in central appetite pathways.</p><p id="P26">In addition to its role in food intake, oxytocin has been implicated in the regulation of energy metabolism. Oxytocin and oxytocin receptor knockout mice develop obesity and reduced thermogenesis without a change in nutrient intake(<xref rid="R6" ref-type="bibr">6</xref>, <xref rid="R32" ref-type="bibr">32</xref>). In an investigation of rats receiving a high fat diet, central oxytocin attenuated weight gain without changing food intake(<xref rid="R7" ref-type="bibr">7</xref>). In another study of diet induced obesity in rats, systemic oxytocin reduced caloric intake and body weight without changing REE, indicating that oxytocin blocked the effect of weight loss to reduce energy expenditure(<xref rid="R33" ref-type="bibr">33</xref>). Chronic subcutaneous administration of oxytocin to obese nonhuman primates increased energy expenditure in the dark cycle by 14% (<xref rid="R11" ref-type="bibr">11</xref>). These studies suggest that oxytocin promotes energy expenditure. A small study of obese men and women found that intranasal oxytocin four times per day led to weight loss of nearly 20 lbs over eight weeks(<xref rid="R12" ref-type="bibr">12</xref>). Although this pilot study was limited by small size and, despite randomization, the groups were not well-matched for age or baseline weight, the weight loss was striking(<xref rid="R12" ref-type="bibr">12</xref>). There were no assessments of appetite, food intake, energy expenditure or activity levels, so the mechanisms of oxytocin effects on weight over time are unclear. Neither our study nor Ott&#x02019;s identified an effect of a single dose of oxytocin on energy expenditure(<xref rid="R14" ref-type="bibr">14</xref>). Whether chronic administration of oxytocin increases energy expenditure remains a key question.</p><p id="P27">Although REE did not differ after oxytocin (vs. placebo) in our study, RQ decreased, consistent with a change in substrate utilization. A study of chronic oxytocin infusion in mice similarly reported a reduction in RQ(<xref rid="R34" ref-type="bibr">34</xref>). Importantly, in our study, there was no difference in caloric intake in the preceding 72 hours in oxytocin or placebo conditions, and subjects abstained from eating, drinking (other than water), and strenous exercise before visits. No subjects were smokers or had respiratory illnesses. Therefore, the RQ difference likely reflects a shift in substrate utilization toward fatty acid oxidation. It has been previously shown that adipocytes and fat progenitor cells have receptors for oxytocin(<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>). <italic>In vitro</italic> and <italic>in vivo</italic> experiments have demonstrated that oxytocin inhibits adipogenesis and promotes lipolytic pathways and fatty acid oxidation(<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R37" ref-type="bibr">37</xref>). In a study of obese nonhuman primates, chronic peripheral administration of oxytocin increased markers of lipolysis(<xref rid="R11" ref-type="bibr">11</xref>). Our finding of a trend toward reduced triglycerides following oxytocin administration is consistent with a possible lipolytic effect.</p><p id="P28">Preclinical research indicates that oxytocin may be involved in glucose homeostasis. Oxytocin knockout mice develop insulin resistance and glucose intolerance(<xref rid="R38" ref-type="bibr">38</xref>). In obese mice, oxytocin reduces fasting insulin secretion and insulin resistance and improves glucose tolerance prior to a change in weight(<xref rid="R12" ref-type="bibr">12</xref>). Peripheral oxytocin administration in rats increases insulin-sensitive glucose transporter 4 mRNA in fat, suggesting a mechanism for increasing insulin sensitivity(<xref rid="R39" ref-type="bibr">39</xref>). Ott et al. showed that intranasal oxytocin reduced postprandial glucose but not insulin levels in healthy men(<xref rid="R14" ref-type="bibr">14</xref>). Our finding in men that a single dose of oxytocin reduces <italic>fasting</italic> insulin secretion and HOMA-IR without affecting glucose levels supports the concept that oxytocin may improve insulin sensitivity independent of its effects on weight. However, Zhang et al. did not show effects of sustained intranasal oxytocin on fasting insulin or glucose levels in a small study of nondiabetic obese men and women(<xref rid="R12" ref-type="bibr">12</xref>). Further research will be important to examine the effects of oxytocin on glucose tolerance in humans, particularly diabetics.</p><p id="P29">This study is limited by a relatively small sample size. It is possible that with more subjects, we may have detected significant differences in appetite, types of calories consumed (e.g., protein or carbohydrate), or REE. Due to potential effects of estrogen and progesterone on oxytocin secretion and receptor distribution, this study focused exclusively on men. Future studies will need to examine oxytocin effects on eating behavior in females, as oxytocin has gender-specific effects(<xref rid="R40" ref-type="bibr">40</xref>). We have demonstrated an acute effect of oxytocin on food intake, substrate utilization, and insulin sensitivity. Whether chronic oxytocin administration would be useful in promoting and maintaining weight loss and improved glucose metabolism in obesity is unknown, and warrants investigation.</p><p id="P30">In summary, in a study of healthy men, we found that a single dose of intranasal oxytocin reduced caloric intake at a breakfast meal without changing subjective appetite or appetite-regulating hormones leptin, ghrelin or PYY. Although oxytocin resulted in a rise in serum CCK levels preceding the oxytocin-induced suppression of food intake, it is not clear from this study whether CCK is a mediator of oxytocin effects. Oxytocin reduced the RQ, indicating a shift in substrate utilization to fatty acid oxidation. Finally, oxytocin reduced fasting insulin and HOMA-IR without changing glucose levels, indicating improved insulin sensitivity. Further investigation of sustained oxytocin safety and effects on caloric intake and metabolism will be important.</p></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>01</label><media xlink:href="NIHMS662890-supplement-01.pdf" orientation="portrait" xlink:type="simple" id="d37e530" position="anchor"/></supplementary-material></sec></body><back><ack id="S20"><title>Acknowledgements</title><p>EAL designed and oversaw the protocol, analyzed and interpreted data and wrote the manuscript. DAM, RLD, CJT carried out experiments. TMH was involved in study design, experiments, and data interpretation. DAS analyzed the data. All authors reviewed, edited and approved the manuscript. Sources of support: NIH K23 MH092560, 1UL1 TR001102-01, 2P30DK046200; MGH Claflin Distinguished Scholar Award. We thank the MGH CRC staff and study participants.</p></ack><fn-group><fn id="FN1"><p id="P31"><bold>Conflict of interest:</bold> The authors declare no conflicts of interest.</p></fn><fn id="FN2"><p id="P32"><xref ref-type="supplementary-material" rid="SD1">Supplementary information</xref> is available at the <italic>Obesity</italic> website.</p></fn><fn id="FN3"><p id="P33"><bold>Clinical Trial Registration Number:</bold> NCT01513499</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogden</surname><given-names>CL</given-names></name><name><surname>Carroll</surname><given-names>MD</given-names></name><name><surname>Kit</surname><given-names>BK</given-names></name><name><surname>Flegal</surname><given-names>KM</given-names></name></person-group><article-title>Prevalence of obesity in the United States, 2009-2010</article-title><source>NCHS data brief</source><year>2012</year><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gloy</surname><given-names>VL</given-names></name><name><surname>Briel</surname><given-names>M</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Kashyap</surname><given-names>SR</given-names></name><name><surname>Schauer</surname><given-names>PR</given-names></name><name><surname>Mingrone</surname><given-names>G</given-names></name><etal/></person-group><article-title>Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials</article-title><source>Bmj</source><year>2013</year><volume>347</volume><fpage>f5934</fpage><pub-id pub-id-type="pmid">24149519</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanovski</surname><given-names>SZ</given-names></name><name><surname>Yanovski</surname><given-names>JA</given-names></name></person-group><article-title>Long-term drug treatment for obesity: a systematic and clinical review</article-title><source>JAMA: the journal of the American Medical Association</source><year>2014</year><volume>311</volume><fpage>74</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24231879</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arletti</surname><given-names>R</given-names></name><name><surname>Benelli</surname><given-names>A</given-names></name><name><surname>Bertolini</surname><given-names>A</given-names></name></person-group><article-title>Influence of oxytocin on feeding behavior in the rat</article-title><source>Peptides</source><year>1989</year><volume>10</volume><fpage>89</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">2748428</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olson</surname><given-names>BR</given-names></name><name><surname>Drutarosky</surname><given-names>MD</given-names></name><name><surname>Chow</surname><given-names>MS</given-names></name><name><surname>Hruby</surname><given-names>VJ</given-names></name><name><surname>Stricker</surname><given-names>EM</given-names></name><name><surname>Verbalis</surname><given-names>JG</given-names></name></person-group><article-title>Oxytocin and an oxytocin agonist administered centrally decrease food intake in rats</article-title><source>Peptides</source><year>1991</year><volume>12</volume><fpage>113</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">1646995</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Takayanagi</surname><given-names>Y</given-names></name><name><surname>Kawada</surname><given-names>T</given-names></name><name><surname>Itoi</surname><given-names>K</given-names></name><name><surname>Nishimori</surname><given-names>K</given-names></name></person-group><article-title>Impaired thermoregulatory ability of oxytocin-deficient mice during cold-exposure</article-title><source>Bioscience, biotechnology, and biochemistry</source><year>2007</year><volume>71</volume><fpage>3122</fpage><lpage>3126</lpage></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deblon</surname><given-names>N</given-names></name><name><surname>Veyrat-Durebex</surname><given-names>C</given-names></name><name><surname>Bourgoin</surname><given-names>L</given-names></name><name><surname>Caillon</surname><given-names>A</given-names></name><name><surname>Bussier</surname><given-names>AL</given-names></name><name><surname>Petrosino</surname><given-names>S</given-names></name><etal/></person-group><article-title>Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats</article-title><source>PloS one</source><year>2011</year><volume>6</volume><fpage>e25565</fpage><pub-id pub-id-type="pmid">21980491</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>EE</given-names></name><name><surname>Billington</surname><given-names>CJ</given-names></name><name><surname>Kotz</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Oxytocin in the ventromedial hypothalamic nucleus reduces feeding and acutely increases energy expenditure</article-title><source>American journal of physiology Regulatory, integrative and comparative physiology</source><year>2014</year><volume>307</volume><fpage>R737</fpage><lpage>745</lpage></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Bai</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Dean</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><etal/></person-group><article-title>Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance</article-title><source>Neuron</source><year>2011</year><volume>69</volume><fpage>523</fpage><lpage>535</lpage><pub-id pub-id-type="pmid">21315262</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Cai</surname><given-names>D</given-names></name></person-group><article-title>Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment</article-title><source>American journal of physiology Endocrinology and metabolism</source><year>2011</year><volume>301</volume><fpage>E1004</fpage><lpage>1012</lpage><pub-id pub-id-type="pmid">21828335</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blevins</surname><given-names>JE</given-names></name><name><surname>Graham</surname><given-names>JL</given-names></name><name><surname>Morton</surname><given-names>GJ</given-names></name><name><surname>Bales</surname><given-names>KL</given-names></name><name><surname>Schwartz</surname><given-names>MW</given-names></name><name><surname>Baskin</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys</article-title><source>American journal of physiology Regulatory, integrative and comparative physiology</source><year>2014</year><comment>ajpregu 00441 02014</comment></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models</article-title><source>PloS one</source><year>2013</year><volume>8</volume><fpage>e61477</fpage><pub-id pub-id-type="pmid">23700406</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borg</surname><given-names>J</given-names></name><name><surname>Simren</surname><given-names>M</given-names></name><name><surname>Ohlsson</surname><given-names>B</given-names></name></person-group><article-title>Oxytocin reduces satiety scores without affecting the volume of nutrient intake or gastric emptying rate in healthy subjects</article-title><source>Neurogastroenterology and motility: the official journal of the European Gastrointestinal Motility Society</source><year>2011</year><volume>23</volume><fpage>56</fpage><lpage>61, e55</lpage><pub-id pub-id-type="pmid">20868426</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ott</surname><given-names>V</given-names></name><name><surname>Finlayson</surname><given-names>G</given-names></name><name><surname>Lehnert</surname><given-names>H</given-names></name><name><surname>Heitmann</surname><given-names>B</given-names></name><name><surname>Heinrichs</surname><given-names>M</given-names></name><name><surname>Born</surname><given-names>J</given-names></name><etal/></person-group><article-title>Oxytocin reduces reward-driven food intake in humans</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>3418</fpage><lpage>3425</lpage><pub-id pub-id-type="pmid">23835346</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonald</surname><given-names>E</given-names></name><name><surname>Dadds</surname><given-names>MR</given-names></name><name><surname>Brennan</surname><given-names>JL</given-names></name><name><surname>Williams</surname><given-names>K</given-names></name><name><surname>Levy</surname><given-names>F</given-names></name><name><surname>Cauchi</surname><given-names>AJ</given-names></name></person-group><article-title>A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research</article-title><source>Psychoneuroendocrinology</source><year>2011</year><volume>36</volume><fpage>1114</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">21429671</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gagnon</surname><given-names>DD</given-names></name><name><surname>Rintamaki</surname><given-names>H</given-names></name><name><surname>Gagnon</surname><given-names>SS</given-names></name><name><surname>Cheung</surname><given-names>SS</given-names></name><name><surname>Herzig</surname><given-names>KH</given-names></name><name><surname>Porvari</surname><given-names>K</given-names></name><etal/></person-group><article-title>Cold exposure enhances fat utilization but not non-esterified fatty acids, glycerol or catecholamines availability during submaximal walking and running</article-title><source>Frontiers in physiology</source><year>2013</year><volume>4</volume><fpage>99</fpage><pub-id pub-id-type="pmid">23675353</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flint</surname><given-names>A</given-names></name><name><surname>Raben</surname><given-names>A</given-names></name><name><surname>Blundell</surname><given-names>JE</given-names></name><name><surname>Astrup</surname><given-names>A</given-names></name></person-group><article-title>Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies</article-title><source>Int J Obes Relat Metab Disord</source><year>2000</year><volume>24</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">10702749</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kublaoui</surname><given-names>BM</given-names></name><name><surname>Gemelli</surname><given-names>T</given-names></name><name><surname>Tolson</surname><given-names>KP</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zinn</surname><given-names>AR</given-names></name></person-group><article-title>Oxytocin deficiency mediates hyperphagic obesity of Sim1 haploinsufficient mice</article-title><source>Molecular endocrinology</source><year>2008</year><volume>22</volume><fpage>1723</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">18451093</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Striepens</surname><given-names>N</given-names></name><name><surname>Kendrick</surname><given-names>KM</given-names></name><name><surname>Hanking</surname><given-names>V</given-names></name><name><surname>Landgraf</surname><given-names>R</given-names></name><name><surname>Wullner</surname><given-names>U</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><etal/></person-group><article-title>Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans</article-title><source>Scientific reports</source><year>2013</year><volume>3</volume><fpage>3440</fpage><pub-id pub-id-type="pmid">24310737</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atasoy</surname><given-names>D</given-names></name><name><surname>Betley</surname><given-names>JN</given-names></name><name><surname>Su</surname><given-names>HH</given-names></name><name><surname>Sternson</surname><given-names>SM</given-names></name></person-group><article-title>Deconstruction of a neural circuit for hunger</article-title><source>Nature</source><year>2012</year><volume>488</volume><fpage>172</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">22801496</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blevins</surname><given-names>JE</given-names></name><name><surname>Schwartz</surname><given-names>MW</given-names></name><name><surname>Baskin</surname><given-names>DG</given-names></name></person-group><article-title>Evidence that paraventricular nucleus oxytocin neurons link hypothalamic leptin action to caudal brain stem nuclei controlling meal size</article-title><source>American journal of physiology Regulatory, integrative and comparative physiology</source><year>2004</year><volume>287</volume><fpage>R87</fpage><lpage>96</lpage></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>N</given-names></name><name><surname>Caquineau</surname><given-names>C</given-names></name><name><surname>Dayanithi</surname><given-names>G</given-names></name><name><surname>Bull</surname><given-names>P</given-names></name><name><surname>Douglas</surname><given-names>AJ</given-names></name><name><surname>Guan</surname><given-names>XM</given-names></name><etal/></person-group><article-title>Alpha-melanocyte-stimulating hormone stimulates oxytocin release from the dendrites of hypothalamic neurons while inhibiting oxytocin release from their terminals in the neurohypophysis</article-title><source>The Journal of neuroscience: the official journal of the Society for Neuroscience</source><year>2003</year><volume>23</volume><fpage>10351</fpage><lpage>10358</lpage><pub-id pub-id-type="pmid">14614094</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinaman</surname><given-names>L</given-names></name></person-group><article-title>Oxytocinergic inputs to the nucleus of the solitary tract and dorsal motor nucleus of the vagus in neonatal rats</article-title><source>The Journal of comparative neurology</source><year>1998</year><volume>399</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">9725704</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCann</surname><given-names>MJ</given-names></name><name><surname>Rogers</surname><given-names>RC</given-names></name></person-group><article-title>Oxytocin excites gastric-related neurones in rat dorsal vagal complex</article-title><source>J Physiol</source><year>1990</year><volume>428</volume><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">2231433</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabatier</surname><given-names>N</given-names></name><name><surname>Leng</surname><given-names>G</given-names></name><name><surname>Menzies</surname><given-names>J</given-names></name></person-group><article-title>Oxytocin, feeding, and satiety</article-title><source>Frontiers in endocrinology</source><year>2013</year><volume>4</volume><fpage>35</fpage><pub-id pub-id-type="pmid">23518828</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sofroniew</surname><given-names>MV</given-names></name></person-group><article-title>Projections from vasopressin, oxytocin, and neurophysin neurons to neural targets in the rat and human</article-title><source>The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society</source><year>1980</year><volume>28</volume><fpage>475</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">7381192</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>CF</given-names></name></person-group><article-title>Inhibition by oxytocin of methamphetamine-induced hyperactivity related to dopamine turnover in the mesolimbic region in mice</article-title><source>Naunyn-Schmiedeberg&#x02019;s archives of pharmacology</source><year>2008</year><volume>376</volume><fpage>441</fpage><lpage>448</lpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullis</surname><given-names>K</given-names></name><name><surname>Kay</surname><given-names>K</given-names></name><name><surname>Williams</surname><given-names>DL</given-names></name></person-group><article-title>Oxytocin action in the ventral tegmental area affects sucrose intake</article-title><source>Brain research</source><year>2013</year><volume>1513</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">23548602</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Hung</surname><given-names>CR</given-names></name><name><surname>Chang</surname><given-names>FY</given-names></name><name><surname>Pau</surname><given-names>KY</given-names></name><name><surname>Wang</surname><given-names>PS</given-names></name></person-group><article-title>Pharmacological effects of oxytocin on gastric emptying and intestinal transit of a non-nutritive liquid meal in female rats</article-title><source>Naunyn-Schmiedeberg&#x02019;s archives of pharmacology</source><year>2003</year><volume>367</volume><fpage>406</fpage><lpage>413</lpage></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Doong</surname><given-names>ML</given-names></name><name><surname>Wang</surname><given-names>PS</given-names></name></person-group><article-title>Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by oxytocin in ovariectomized rats</article-title><source>European journal of pharmacology</source><year>2008</year><volume>580</volume><fpage>407</fpage><lpage>415</lpage><pub-id pub-id-type="pmid">18078924</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vila</surname><given-names>G</given-names></name><name><surname>Riedl</surname><given-names>M</given-names></name><name><surname>Resl</surname><given-names>M</given-names></name><name><surname>van der Lely</surname><given-names>AJ</given-names></name><name><surname>Hofland</surname><given-names>LJ</given-names></name><name><surname>Clodi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Systemic administration of oxytocin reduces basal and lipopolysaccharide-induced ghrelin levels in healthy men</article-title><source>The Journal of endocrinology</source><year>2009</year><volume>203</volume><fpage>175</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">19587265</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takayanagi</surname><given-names>Y</given-names></name><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Onaka</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>N</given-names></name><name><surname>Kawada</surname><given-names>T</given-names></name><name><surname>Nishimori</surname><given-names>K</given-names></name></person-group><article-title>Oxytocin receptor-deficient mice developed late-onset obesity</article-title><source>Neuroreport</source><year>2008</year><volume>19</volume><fpage>951</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">18520999</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morton</surname><given-names>GJ</given-names></name><name><surname>Thatcher</surname><given-names>BS</given-names></name><name><surname>Reidelberger</surname><given-names>RD</given-names></name><name><surname>Ogimoto</surname><given-names>K</given-names></name><name><surname>Wolden-Hanson</surname><given-names>T</given-names></name><name><surname>Baskin</surname><given-names>DG</given-names></name><etal/></person-group><article-title>Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats</article-title><source>American journal of physiology Endocrinology and metabolism</source><year>2012</year><volume>302</volume><fpage>E134</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">22008455</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maejima</surname><given-names>Y</given-names></name><name><surname>Iwasaki</surname><given-names>Y</given-names></name><name><surname>Yamahara</surname><given-names>Y</given-names></name><name><surname>Kodaira</surname><given-names>M</given-names></name><name><surname>Sedbazar</surname><given-names>U</given-names></name><name><surname>Yada</surname><given-names>T</given-names></name></person-group><article-title>Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass</article-title><source>Aging</source><year>2011</year><volume>3</volume><fpage>1169</fpage><lpage>1177</lpage><pub-id pub-id-type="pmid">22184277</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gould</surname><given-names>BR</given-names></name><name><surname>Zingg</surname><given-names>HH</given-names></name></person-group><article-title>Mapping oxytocin receptor gene expression in the mouse brain and mammary gland using an oxytocin receptor-LacZ reporter mouse</article-title><source>Neuroscience</source><year>2003</year><volume>122</volume><fpage>155</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">14596857</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaffler</surname><given-names>A</given-names></name><name><surname>Binart</surname><given-names>N</given-names></name><name><surname>Scholmerich</surname><given-names>J</given-names></name><name><surname>Buchler</surname><given-names>C</given-names></name></person-group><article-title>Hypothesis paper Brain talks with fat--evidence for a hypothalamic-pituitary-adipose axis?</article-title><source>Neuropeptides</source><year>2005</year><volume>39</volume><fpage>363</fpage><lpage>367</lpage><pub-id pub-id-type="pmid">16040119</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elabd</surname><given-names>C</given-names></name><name><surname>Basillais</surname><given-names>A</given-names></name><name><surname>Beaupied</surname><given-names>H</given-names></name><name><surname>Breuil</surname><given-names>V</given-names></name><name><surname>Wagner</surname><given-names>N</given-names></name><name><surname>Scheideler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis</article-title><source>Stem cells</source><year>2008</year><volume>26</volume><fpage>2399</fpage><lpage>2407</lpage><pub-id pub-id-type="pmid">18583541</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camerino</surname><given-names>C</given-names></name></person-group><article-title>Low sympathetic tone and obese phenotype in oxytocin-deficient mice</article-title><source>Obesity</source><year>2009</year><volume>17</volume><fpage>980</fpage><lpage>984</lpage><pub-id pub-id-type="pmid">19247273</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eckertova</surname><given-names>M</given-names></name><name><surname>Ondrejcakova</surname><given-names>M</given-names></name><name><surname>Krskova</surname><given-names>K</given-names></name><name><surname>Zorad</surname><given-names>S</given-names></name><name><surname>Jezova</surname><given-names>D</given-names></name></person-group><article-title>Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis</article-title><source>British journal of pharmacology</source><year>2011</year><volume>162</volume><fpage>452</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">20846187</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>CS</given-names></name><name><surname>Boone</surname><given-names>EM</given-names></name><name><surname>Pournajafi-Nazarloo</surname><given-names>H</given-names></name><name><surname>Bales</surname><given-names>KL</given-names></name></person-group><article-title>Consequences of early experiences and exposure to oxytocin and vasopressin are sexually dimorphic</article-title><source>Developmental neuroscience</source><year>2009</year><volume>31</volume><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">19546570</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text position="float" id="BX1" orientation="portrait"><sec id="S21"><title>What is known</title><list list-type="bullet" id="L1"><list-item><p>Oxytocin is a peptide hormone produced in the hypothalamus.</p></list-item><list-item><p>In animal models, oxytocin reduces caloric intake and has positive metabolic effects.</p></list-item><list-item><p>In a small study of humans, intranasal oxytocin over eight weeks led to weight loss.</p></list-item><list-item><p>Intranasal oxytocin has central actions with minimal side effects.</p></list-item></list></sec><sec id="S22"><title>What does this study add</title><list list-type="bullet" id="L2"><list-item><p>A single dose of intranasal oxytocin reduces caloric intake in men without effects on subjective hunger or satiety, or mediation by established endocrine regulators of food intake.</p></list-item><list-item><p>In addition, oxytocin reduces the fasting respiratory quotient in men, consistent with a shift in substrate utilization toward fatty acid oxidation.</p></list-item><list-item><p>Oxytocin also reduces fasting insulin levels in men without affecting glucose levels, indicating improved insulin sensitivity.</p></list-item></list></sec></boxed-text><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Study schema. VAS, visual analogue scales. OT, oxytocin. Filled in diamonds, blood draws.</p></caption><graphic xlink:href="nihms-662890-f0001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Compared to placebo, oxytocin reduced A.) total caloric intake by 122&#x000b1;51 kcal, B.) fat intake by 8.7&#x000b1;3.8 g, C.) protein intake by 3.9&#x000b1;2.2 g, and D.) carbohydrate content by 7.2&#x000b1;9.4g. *, p=0.03. <sup>&#x000a5;</sup>, no longer significant after controlling for multiple comparisons.</p></caption><graphic xlink:href="nihms-662890-f0002"/></fig><table-wrap id="T1" position="float" orientation="landscape"><label>Table 1</label><caption><title>Energy intake and expenditure</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Oxytocin</th><th align="center" valign="bottom" rowspan="1" colspan="1">Placebo</th><th align="center" valign="bottom" rowspan="1" colspan="1">Least Squared<break/>Mean Difference</th><th align="center" valign="bottom" rowspan="1" colspan="1">p-value</th></tr></thead><tbody><tr><td colspan="5" align="left" valign="top" rowspan="1">
<italic>Food diary (kcal/24 hr in 72 hrs prior to study visit)</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total calories (kcal)</td><td align="center" valign="top" rowspan="1" colspan="1">1930&#x000b1;56</td><td align="center" valign="top" rowspan="1" colspan="1">1920&#x000b1;58</td><td align="center" valign="top" rowspan="1" colspan="1">11&#x000b1;80</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Protein (g)</td><td align="center" valign="top" rowspan="1" colspan="1">73.6&#x000b1;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">81.9&#x000b1;2.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;2.3&#x000b1;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Carbohydrate (g)</td><td align="center" valign="top" rowspan="1" colspan="1">226.8&#x000b1;7.9</td><td align="center" valign="top" rowspan="1" colspan="1">226.9&#x000b1;8.2</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.1&#x000b1;11.3</td><td align="center" valign="top" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fat (g)</td><td align="center" valign="top" rowspan="1" colspan="1">77.6&#x000b1;2.5</td><td align="center" valign="top" rowspan="1" colspan="1">74.6&#x000b1;2.6</td><td align="center" valign="top" rowspan="1" colspan="1">3.0&#x000b1;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<italic>Fasting indirect calorimetry</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Resting energy expenditure (kcal)</td><td align="center" valign="top" rowspan="1" colspan="1">1484&#x000b1;22</td><td align="center" valign="top" rowspan="1" colspan="1">1479&#x000b1;22</td><td align="center" valign="top" rowspan="1" colspan="1">5.8&#x000b1;31.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;RQ</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.79&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.82&#x000b1;0.02</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.03&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.02</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fat utilization (g/min)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.07&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.06&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.01&#x000b1;0.00</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Carbohydrate utilization (g/min)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.08&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.11&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;0.02&#x000b1;0.01</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.03</bold>
</td></tr><tr><td colspan="5" align="left" valign="top" rowspan="1">
<italic>Meal</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total calories ordered (kcal)</td><td align="center" valign="top" rowspan="1" colspan="1">853&#x000b1;27</td><td align="center" valign="top" rowspan="1" colspan="1">878&#x000b1;27</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;25.1&#x000b1;37.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Total calories consumed (kcal)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>1153&#x000b1;36</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>1275&#x000b1;36</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;122&#x000b1;51</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.03</bold>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Protein ordered (g)</td><td align="center" valign="top" rowspan="1" colspan="1">24.5&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">25.7&#x000b1;1.3</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.2&#x000b1;1.8</td><td align="center" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Protein consumed (g)</td><td align="center" valign="top" rowspan="1" colspan="1">34.9&#x000b1;1.5</td><td align="center" valign="top" rowspan="1" colspan="1">38.8&#x000b1;1.5</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.9&#x000b1;2.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Carbohydrate ordered (g)</td><td align="center" valign="top" rowspan="1" colspan="1">119.0&#x000b1;5.3</td><td align="center" valign="top" rowspan="1" colspan="1">115.7&#x000b1;5.3</td><td align="center" valign="top" rowspan="1" colspan="1">3.3&#x000b1;7.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Carbohydrates consumed (g)</td><td align="center" valign="top" rowspan="1" colspan="1">148.4&#x000b1;6.6</td><td align="center" valign="top" rowspan="1" colspan="1">155.6&#x000b1;6.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;7.2&#x000b1;9.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fat ordered (g)</td><td align="center" valign="top" rowspan="1" colspan="1">31.7&#x000b1;1.7</td><td align="center" valign="top" rowspan="1" colspan="1">35.5&#x000b1;1.7</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;3.8&#x000b1;2.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fat consumed (g)</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>47.3&#x000b1;2.7</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>56.0&#x000b1;2.7</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>&#x02212;8.7&#x000b1;3.8</bold>
</td><td align="center" valign="top" rowspan="1" colspan="1">
<bold>0.03<xref ref-type="table-fn" rid="TFN1">&#x000a5;</xref></bold>
</td></tr></tbody></table><table-wrap-foot><p>Mean&#x000b1;SEM</p><p>Bold typeface indicates p-value &#x0003c;0.05</p><fn id="TFN1"><label>&#x000a5;</label><p id="P34">, no longer significant after controlling for multiple comparisons</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2</label><caption><p>Treatment effect of oxytocin on fasting levels of hormones, triglycerides and glucose</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">Mean<break/>Baseline Value</th><th align="center" valign="bottom" rowspan="1" colspan="1">Treatment<break/>Effect Estimate</th><th align="center" valign="bottom" rowspan="1" colspan="1">P-value<xref ref-type="table-fn" rid="TFN2">*</xref></th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Insulin (uU/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">7.0&#x000b1;0.9</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;1.7&#x000b1;0.8</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Glucose (mg/dL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">84.6&#x000b1;1.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;0.1&#x000b1;0.5</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">HOMA-IR</td><td align="center" valign="bottom" rowspan="1" colspan="1">1.5&#x000b1;0.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;0.4&#x000b1;0.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>0.04</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Triglycerides (mg/dL )</td><td align="center" valign="bottom" rowspan="1" colspan="1">103.1&#x000b1;7.4</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;1.8&#x000b1;1.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Oxytocin (pg/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">965.0&#x000b1;53.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;32.5&#x000b1;20.7</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">CCK (pg/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">72.5&#x000b1;11.0</td><td align="center" valign="bottom" rowspan="1" colspan="1">10.9&#x000b1;3.1</td><td align="center" valign="bottom" rowspan="1" colspan="1">
<bold>0.002</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Leptin (ng/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">3.7&#x000b1;0.5</td><td align="center" valign="bottom" rowspan="1" colspan="1">&#x02212;0.1&#x000b1;0.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">Active Ghrelin (pg/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">92.2&#x000b1;6.1</td><td align="center" valign="bottom" rowspan="1" colspan="1">14.4&#x000b1;12.1</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">PYY (pg/mL)</td><td align="center" valign="bottom" rowspan="1" colspan="1">61.9&#x000b1;5.2</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.6&#x000b1;2.5</td><td align="center" valign="bottom" rowspan="1" colspan="1">0.8</td></tr></tbody></table><table-wrap-foot><p>Mean&#x000b1;SEM</p><p>Bold typeface indicates p-value &#x0003c;0.05</p><fn id="TFN2"><label>*</label><p id="P35">p-value, overall repeated measures</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="landscape"><label>Table 3</label><caption><p>Adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<bold>Oxytocin</bold>
</th><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<bold>Placebo</bold>
</th><th align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Mild</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Moderate</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Total</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Mild</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Moderate</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>Total</italic>
</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Dizziness</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drowsiness</td><td align="center" valign="top" rowspan="1" colspan="1">5</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">6</td><td align="center" valign="top" rowspan="1" colspan="1">4</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dry oropharynx</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nasal irritation/rhinorrhea</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abdominal pain</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anxiety</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Headache</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td><td align="center" valign="top" rowspan="1" colspan="1">0</td></tr></tbody></table></table-wrap></floats-group></article>